Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Sri Kosaraju
AddedMar 31, 2024
UpdatedMay 31, 2026
Sri Kosaraju

Sri Kosaraju

Board Member, Nevro

CrunchbaseLinkedIn

Sri Kosaraju's Career

Nevro
Nevro

Redwood City, CA, US

Board Member· Board
10x Genomics
10x Genomics

Pleasanton, CA, US

Board Member· Board
Inscripta
Inscripta

Boulder, CO, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Sri Kosaraju's Career

Nevro
Nevro
Public$555.8M1.1k2006Redwood City, CA, US
Board Member· Board

Leadership at Nevro

Frank FischerFrank FischerBoard Member
Kevin ThornalKevin ThornalBoard Member
D. Keith GrossmanD. Keith GrossmanBoard Member
Karen PrangeKaren PrangeBoard Member
Bess WeathermanBess WeathermanBoard Member
Kevin O'BoyleKevin O'BoyleBoard Member
10x Genomics
10x Genomics
Public$242.6M4482012Pleasanton, CA, US
Board Member· Board

Recent news

Genetics testing startup Nucleus Genomics criticized for its embryo product: ‘Makes me so nauseous’Startups | TechCrunch · 2025
Promise Bio exits stealth backed by Pfizer and AstraZenecaTechCrunch · 2024

Leadership at 10x Genomics

Ben HindsonBen HindsonBoard Member
Bryan RobertsBryan RobertsBoard Member
Shehnaaz SulimanShehnaaz SulimanBoard Member
Paul ConleyPaul ConleyBoard Member
John StuelpnagelJohn StuelpnagelBoard Member
Serge SaxonovSerge SaxonovCo-Founder

Similar to 10x Genomics

Singular GenomicsSingular GenomicsSan Diego, CA, USGenomic Technologiesest. 2016Singular GenomicsSan Diego, CA, US · est. 2016

Singular Genomics: A dynamic, fast-paced biotech company in California, innovating in genomic technologies.

Public · $176M134
Spatial GenomicsSpatial GenomicsPasadena, CA, USGenomic Analysisest. 2016Spatial GenomicsPasadena, CA, US · est. 2016

Pioneering spatial analysis and comprehensive single-cell assay in intact cells and tissues.

Series A · $56M24
Pacific Biosciences of CaliforniaPacific Biosciences of CaliforniaMenlo Park, CA, USGenetic Analysis, Sequencing Systemsest. 2004Pacific Biosciences of CaliforniaMenlo Park, CA, US · est. 2004

Pacific Biosciences, a CA-based medical firm, designs and manufactures sequencing systems for complex genetic analysis.

Public · $2B769
XGenomesXGenomesCambridge, MA, USDNA Sequencingest. 2017XGenomesCambridge, MA, US · est. 2017

XGenomes: Revolutionizing DNA sequencing with fast, accurate, and affordable technology for health monitoring.

Angel · $350k9
Inscripta
Inscripta
Series A$463.9M1782015Boulder, CO, US
CEO· C-Suite · Management

Leadership at Inscripta

Ryan T. GillRyan T. GillCo-Founder
Roger WyseRoger WyseBoard Member
Andrew GarstAndrew GarstCo-Founder
Tanya WarneckeTanya WarneckeCo-Founder

Similar to Inscripta

SynthegoSynthegoRedwood City, CA, USCrispr Kits, Gene Editingest. 2012SynthegoRedwood City, CA, US · est. 2012

US-based Synthego Corp. provides software solutions for biological research, primarily serving California.

Series E · $460.5M322
Mammoth BiosciencesMammoth BiosciencesSan Francisco, CA, USCrispr Productsest. 2017Mammoth BiosciencesSan Francisco, CA, US · est. 2017

Mammoth Biosciences: An American biotech firm innovating CRISPR products to improve lives.

Series D · $264.5M195
Ginkgo BioworksGinkgo BioworksBoston, MA, USOrganism Designest. 2009Ginkgo BioworksBoston, MA, US · est. 2009

Ginkgo Bioworks: Engineering biology, designing custom organisms for diverse markets.

Public · $1.6B1.3k
Tome BiosciencesTome BiosciencesWatertown, MA, USGene Editingest. 2021Tome BiosciencesWatertown, MA, US · est. 2021

Tome Biosciences: Pioneering programmable gene insertion via CRISPR for precise genome editing.

Series A · $213M88

Sri Kosaraju's Similar Executives & Operators

Willix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Sri Kosaraju

Sudhir Kumar SinhaSudhir Kumar SinhaCo-Founder · Cadex GenomicsEric DahlhauserEric DahlhauserBoard Member · Insight GeneticsRonan BurkeRonan BurkeCo-Founder & CEO · InscribeJiarui LiJiarui LiCEO · Innatrix